Research and Markets (http://www.researchandmarkets.com/research/332a00/the_future_of_hiv)
has announced the addition of the "The
Future of HIV Therapeutics - Market Forecasts to 2015, Competitive
Benchmarking, Product Pipeline and Deals Analysis" report to their
offering.
"The
Future of HIV Therapeutics - Market Forecasts to 2015, Competitive
Benchmarking, Product Pipeline and Deals Analysis" provides in-depth
analysis of unmet needs, drivers and barriers that impact the global HIV
therapeutics market. The report analyzes the markets for HIV
therapeutics in the US, the top five countries in Europe (the UK,
Germany, France, Italy and Spain) and Japan. Treatment usage patterns,
sales, price and volume are forecast until 2015 for the key geographies.
Further, the report provides competitive benchmarking for the leading
companies and also analyzes the mergers, acquisitions and licensing
agreements that shape the global market.
The HIV Market will Grow Moderately Driven Decreased Mortality and
Increased Usage; Growth Will be Impacted by Patent Expiries
The HIV market is growing moderately and is dominated by the US. The
growth rate is likely to decline from 2012 onwards due to the impact of
patent expiry of key drugs. However, migration to new branded drugs is
likely to minimize the impact of generics, which currently account for
approximately 7.8% of the market.
The global HIV therapeutics market is expected to grow at a CAGR of 3.7%
from $10.8 billion in 2008 to $13.9 billion in 2015. This growth will be
driven by increase in prescription rate and increased usage of newer
drugs such as Atripla as part of Highly Active Antiretroviral Therapy
(HAART) HAART involves taking different classes of drugs together as a
therapy. The HIV market is growing at a slower rate than in previous
years. This is primarily due to the patent expiry of major drugs such as
Sustiva and Combivir in 2012. However the impact of patent expiration
will be offset by the increased usage of newer drugs which are more
effective in tackling the progression of the disease. Approximately 1.5
million people infected with HIV received antiretroviral treatment (ART)
in 2008 which will increase at a 6% CAGR during 2008-2015. In addition,
the average annual cost of therapy for ART is forecast to increase at a
higher rate over the next three years with an expected price decline
from 2012 onwards due to a series of patent expirations. However, the
impact of patent expiry is likely to reduce in 2015.
The late stage pipeline drugs such as Rilpivirine by Tibotec
Pharmaceuticals and Vicriviroc by Schering-Plough are expected to enter
market later in the 2008-2015 period and will positively impact the
market. As a result, the HIV market value is going to see a moderate
increase over the time period 2008-2015. The US is the largest HIV
market among the top countries covered. It accounts for approximately
70% of the total market and is followed by Europe which comprises the
UK, France, Italy, Spain, and Germany. Japan accounts for approximately
1% of the market and will experience the highest growth in the
geographies studied. This growth in the Japanese HIV markets will be
driven by an increase in the number of people affected by the virus and
the number of people getting diagnosed and subsequently starting
treatment. Currently Japan has very low prevalence levels.
Scope
The scope of this report includes: